
BMEA Stock Forecast & Price Target
BMEA Analyst Ratings
Bulls say
Biomea Fusion is attractive because icovamenib appears to be a differentiated, disease-modifying asset with confirmatory Phase 2 programs already underway: COVALENT-211 enrolled 64 participants across 18 sites and is due to report 26-week data in 1Q27, while COVALENT-212 is expected to finish enrollment by YE26 with topline data in 2Q27. The company also has early but encouraging breadth from BMF-650, which delivered 1.5% to 3.2% mean day-29 weight loss across active cohorts and 6.1% in the confined cohort, alongside mostly mild or moderate adverse events and no severe, serious, or treatment-related discontinuations, supporting a potentially partnerable oral GLP-1 profile. Taken together, the pipeline offers two shots on goal in high-need metabolic markets, with mechanistic data, tolerability, and upcoming readouts providing multiple catalysts that could de-risk development and broaden strategic interest.
Bears say
Biomea Fusion is viewed negatively because its lead programs, icovamenib and BMF-650, remain early and unproven, with efficacy and safety needing confirmation in larger, controlled trials after only encouraging preclinical and short-course Phase 2 signals. The apparent A1c benefit may be vulnerable to small subgroup effects, post-hoc analysis, and non-monotonic dose-response, while later studies could reveal weaker durability or hepatic and off-target risks. Financially, the company is still generating operating losses, is not expected to be profitable before commercialization, and may need additional capital with potentially dilutive impact, all while facing intense competition in diabetes and obesity markets.
This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.
BMEA Analyst Forecast & Price Prediction
Start investing in BMEA
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Biomea Fusion Inc (BMEA) Forecast
BMEA Analyst Forecast & Price Prediction
Start investing in BMEA
Order type
Buy in
Order amount
Est. shares
0 shares